{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-083850","form_type":"8-K","ticker":"CVRX","cik":"0001235912","company_name":"CVRx, Inc.","filed_at":"2023-07-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.370130+00:00","generated_at":"2026-06-13T02:52:09.147534+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"CVRx Q2 revenue $9.5M (+89% YoY); raises FY 2023 revenue guidance","bullets":["Q2 total revenue $9.5M, +89% YoY; US HF revenue $8.3M, +119% YoY.","Net loss $11.7M ($0.56 per share) vs $11.1M ($0.54 per share) in Q2 2022.","Active US implanting centers grew to 140, up 97% from June 2022.","FY 2023 revenue guidance raised to $37.0-38.5M (from $35.5-38.0M).","PMA supplement filed with FDA for Barostim indication expansion in June 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-083850","json":"https://secwatch.observer/filing/0001104659-23-083850.json","markdown":"https://secwatch.observer/filing/0001104659-23-083850.md","text":"https://secwatch.observer/filing/0001104659-23-083850.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1235912/000110465923083850/0001104659-23-083850-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1235912/000110465923083850/tm2321888d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T02:52:09.147534+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"001e358dae188a8a2c821d76c97a1328f5f5c798","claim":"CVRx, Inc. reported the quarter ended June 30, 2023 results: revenue $9.5 million, net income $11.7 million, EPS $0.56 per share. Guidance raised.","evidence_excerpt":"diseases, today announced its financial and operating results for the second quarter of 2023. Recent Highlights · Total revenue for the second quarter of 2023 was $ 9.5 million, an increase of 89 % over prior year quarter · U.S. Heart Failure (HF) revenue for the second quarter of 2023 was $ 8.3 million compared to $ 3.8 in the prior year quarter, an","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1235912/000110465923083850/0001104659-23-083850-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended June 30, 2023"},{"label":"Revenue","value":"$9.5 million"},{"label":"Net income","value":"$11.7 million"},{"label":"EPS","value":"$0.56 per share"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}